QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Summary

This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.

Timeline

Start

2026-03-05

Primary completion

2027-10-07

Completion

2028-02-28

Drugs

Indications